VAXCYTE, INC. Proceeds from Common Stock Issued
VAXCYTE, INC. (PCVX) reported Proceeds from Common Stock Issued of $195.94 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2025-02-25
- VAXCYTE, INC. proceeds from issuance of common stock for the quarter ending 2024-12-31 was -$26.00K.
- VAXCYTE, INC. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $89.46M, a 82.57% increase year-over-year.
- VAXCYTE, INC. proceeds from issuance of common stock for the quarter ending 2024-06-30 was $106.51M.
- VAXCYTE, INC. proceeds from issuance of common stock for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- VAXCYTE, INC. proceeds from issuance of common stock for fiscal 2024 was $195.94M, a 115.94% increase from fiscal 2023.
- VAXCYTE, INC. proceeds from issuance of common stock for fiscal 2023 was $90.74M, a 6.74% decline from fiscal 2022.
- VAXCYTE, INC. proceeds from issuance of common stock for fiscal 2022 was $97.30M, a 600.19% increase from fiscal 2021.
- VAXCYTE, INC. proceeds from issuance of common stock for fiscal 2021 was $13.90M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $89.43M derived: sum of 2 quarters · filed 2025-02-25 | $195.94M derived: sum of 3 quarters · filed 2025-02-25 | $195.94M 10-K · filed 2025-02-25 |
| 2024-09-30 | $89.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $195.97M derived: sum of 2 quarters · filed 2024-11-05 | $195.97M 10-Q · filed 2024-11-05 | $195.92M derived: sum of 4 quarters · filed 2025-02-25 |
| 2024-06-30 | $106.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $106.51M 10-Q · filed 2024-08-06 | $106.46M derived: sum of 3 quarters · filed 2025-02-25 | $155.46M derived: sum of 4 quarters · filed 2025-02-25 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | -$46.00K derived: sum of 2 quarters · filed 2025-02-25 | $48.95M derived: sum of 3 quarters · filed 2025-02-25 | $48.95M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-12-31 | -$46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $48.95M derived: sum of 2 quarters · filed 2025-02-25 | $48.95M derived: sum of 3 quarters · filed 2025-02-25 | $90.74M 10-K · filed 2025-02-25 |
| 2023-09-30 | $49.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $49.00M derived: sum of 2 quarters · filed 2024-11-05 | $90.79M 10-Q · filed 2024-11-05 | $92.85M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $41.79M 10-Q · filed 2024-08-06 | $43.85M derived: sum of 3 quarters · filed 2025-02-25 | $86.97M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $41.79M 10-Q · filed 2024-05-08 | $43.85M derived: sum of 2 quarters · filed 2025-02-25 | $86.97M derived: sum of 3 quarters · filed 2025-02-25 | $135.97M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $45.18M derived: sum of 2 quarters · filed 2025-02-25 | $94.18M derived: sum of 3 quarters · filed 2025-02-25 | $97.30M 10-K · filed 2025-02-25 |
| 2022-09-30 | $43.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $92.12M derived: sum of 2 quarters · filed 2023-11-06 | $95.24M 10-Q · filed 2023-11-06 | $102.03M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $49.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $52.12M 10-Q · filed 2023-08-08 | $58.91M derived: sum of 3 quarters · filed 2024-02-27 | $66.01M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $3.12M 10-Q · filed 2023-05-08 | $9.90M derived: sum of 2 quarters · filed 2024-02-27 | $17.01M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2021-12-31 | $6.79M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $13.90M derived: sum of 2 quarters · filed 2024-02-27 | $13.90M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $7.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $7.11M 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |